Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. Abstract Text:

BACKGROUND: Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors. OBJECTIVE: Our objective was to determine whether risedronate, 35 mg weekly, is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause. DESIGN: The study was a randomized, double-blind, placebo-controlled clinical trial over 12 months. SETTING AND PARTICIPANTS: Participants included 87 newly postmenopausal women with status post chemotherapy, recruited from a breast cancer clinic in an academic medical center. INTERVENTION: Participants were randomly assigned to receive risedronate 35 mg/wk or placebo. MAIN OUTCOME MEASURES: The primary outcomes were the 12-month changes in spine and hip bone mineral density. Secondary outcomes included changes in markers of bone resorption (urine N-telopeptide cross-linked collagen type I) and formation (osteocalcin, N-terminal propeptide of type I procollagen, and bone-specific alkaline phosphatase). RESULTS: After 12 months, bone mineral density increased by 1.2% at the spine and 1.3% at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9% at the spine and 0.8% at the hip (P < 0.01, difference between groups). N-telopeptide cross-linked collagen type I, a marker of bone resorption, decreased by 19.3%, and N-terminal propeptide of type I procollagen, a marker of bone formation, decreased by 26.6% in participants on active therapy compared with increases in the control group. Risedronate was well tolerated, and the retention rate was 95% at 1 yr. CONCLUSIONS: Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy. Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors.

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. Publishing Authors By Initials

For similar musculoskeletal diseases: bone diseases: bone diseases, metabolic: osteoporosis: osteoporosis, postmenopausal research abstracts see: musculoskeletal diseases: bone diseases: bone diseases, metabolic: osteoporosis: osteoporosis, postmenopausal research

PUBMED ID PMID:

MEDLINE DATE:

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The Journal of clinical endocrinology and metaboli

VOLUME: 92

Page Numbers: 131-6

Journal Abbreviation: J. Clin. Endocrinol. Metab.

ISSN: 0021-972X

DAY: 17

MONTH: 10

YEAR: 2006

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 375362

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. Keywords Mesh Terms:

KEYWORDS: Osteoporosis, Postmenopausal

MESH TERMS: prevention & control

Chemical & Substance for Abstract: Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. Information

Substance Name: Etidronic Acid

Registry Number: 2809-21-4

Grant and Affiliation Information for Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.

AFFILIATION: Department of Medicine, University of Pittsburgh, 3471 Fifth Avenue, Suite 1110, Pittsburgh, Pennsylvania 15213-3221, USA. greenspans@dom.pitt.edu

Country: United States

AGENCY: United States NCRR

GRANT: M01-RR00056

ACRONYM: RR

MEDLINETA: J Clin Endocrinol Metab

REFSOURCE: J Clin Endocrinol Metab. 2007 Jan;92(1):

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial Related Publications

• A FRET map of membrane anchors suggests distinct microdomains of heterotrimeric G proteins.
• Alterations of mesenchymal and endothelial cells in inflammatory bowel diseases.
• Cell-penetrating TIR BB loop decoy peptides a novel class of TLR signaling inhibitors and a tool to study topology of TIR-TIR interactions.
• Cholesterol-lowering drugs may boost bones.
• Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide.
• Cutting Edge: Differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs.
• Evidence supporting the hypothesis that one of the main functions of the aryl hydrocarbon receptor is mediation of cell stress responses.
• Hemicentins assemble on diverse epithelia in the mouse.
• How the headpiece hinge angle is opened: New insights into the dynamics of integrin activation.
• IFN regulatory factor-2 regulates macrophage apoptosis through a STAT1/3- and caspase-1-dependent mechanism.
• Identification of non-dot/icm suppressors of the Legionella pneumophila DeltadotL lethality phenotype.
• Identification of the core transmembrane complex of the Legionella Dot/Icm type IV secretion system.
• Living in a physical world X. Pumping fluids through conduits.
• Oxidative stress, nitric oxide, and the mechanisms of cell death in Lurcher Purkinje cells.
• Phosphorylation of DARPP-32 regulates breast cancer cell migration downstream of the receptor tyrosine kinase DDR1.
• Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
• Rays as weapons.
• Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance.
• Role of phosphatidylinositol-3 kinase in transcriptional regulation of TLR-induced IL-12 and IL-10 by Fc gamma receptor ligation in murine macrophages.
• Search for persons.
• Selective assembly of fibulin-1 splice variants reveals distinct extracellular matrix networks and novel functions for perlecan/UNC-52 splice variants.
• The All-trans-15-syn-retinal chromophore of metarhodopsin III is a partial agonist and not an inverse agonist.
• Thymus development in Macaca fascicularis (Cynomolgus monkey): an approach for toxicology and embryology.
• Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages.
• Transcriptional regulation of lipopolysaccharide (LPS)-induced Toll-like receptor (TLR) expression in murine macrophages: role of interferon regulatory factors 1 (IRF-1) and 2 (IRF-2).
• Uncoiling mechanics of Escherichia coli type I fimbriae are optimized for catch bonds.
• Vehicles, containers, railway wagons.
• War and migration.
• Weapons of mass destruction, WMD.
• [A New Antiphlogistic Principle from Sabal serrulata, II.]